Journal
CLINICAL CANCER RESEARCH
Volume 29, Issue 15, Pages 2745-2747Publisher
AMER ASSOC CANCER RESEARCH
DOI: 10.1158/1078-0432.CCR-23-1043
Keywords
-
Categories
Ask authors/readers for more resources
Circulating tumor DNA (ctDNA) can be measured in the majority of metastatic castration-resistant prostate cancer patients. Data suggest that ctDNA at baseline can be used as a prognostic biomarker, and changes in ctDNA after treatment can rapidly predict both time to progression and survival.
Circulating tumor DNA (ctDNA) is measurable in the majority of metastatic castration-resistant prostate cancer patients. Data indicate that ctDNA present at baseline can serve as a prognostic biomarker and changes in the ctDNA posttreatment can rapidly predict both time to progression and survival.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
